"Only about half the states currently provide coverage for these drugs for non-diabetes purposes," she said
Semaglutide, a GLP-1 receptor agonist, improves glycemic control and weight but is limited by gastrointestinal (GI) side effects, notably nausea, vomiting, and diarrhea, which impair adherence
Understanding why dual-GLP-1 therapy is unsafe, and what precision alternatives exist, is essential for anyone pursuing effective, personalized weight loss
Post mortem evaluation of inflammation, oxidative stress, and PPARgamma activation in a nonhuman primate model of cardiac sympathetic neurodegeneration
Semaglutide is a prescription peptide medication, not a controlled substance, and isnt included in standard screening panels
If you delay exercise until after stopping treatment, establishing new routines becomes harder while hunger is simultaneously increasing